@article{a9ae4f7b72cc4df09788c46264888f08,
title = "Highly sensitive MRD tests for ALL based on the IKZF1 Δ3-6 microdeletion",
keywords = "DNA, Neoplasm/genetics, Feasibility Studies, Humans, Ikaros Transcription Factor/genetics, Neoplasm Recurrence, Local/diagnosis, Neoplasm, Residual/diagnosis, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma/physiopathology, Predictive Value of Tests, Risk Assessment, Sequence Deletion",
author = "Venn, \{N C\} and \{van der Velden\}, \{V H J\} and \{de Bie\}, M and E Waanders and Giles, \{J E\} and T Law and Kuiper, \{R P\} and \{de Haas\}, V and Mullighan, \{C G\} and M Haber and Marshall, \{G M\} and Norris Md and \{van Dongen\}, \{J J M\} and R Sutton",
note = "Funding Information: We acknowledge the NH\&MRC and the Cancer Council NSW for their financial support of the Australian MRD studies, and clinicians participating in the ANZCHOG Study 8 trial particularly Dr L Dalla Pozza. Standardization and quality control for MRD testing is supported by the EuroMRD (previously ESG-MRD-ALL) group. Children{\textquoteright}s Cancer Institute Australia for Medical Research is affiliated with both the University of New South Wales and Sydney Children{\textquoteright}s Hospital.",
year = "2012",
month = jun,
doi = "10.1038/leu.2011.348",
language = "English",
volume = "26",
pages = "1414--6",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Springer Nature",
number = "6",
}